Janus激酶抑制剂在中重度特应性皮炎中的应用进展

doi:10.35541/cjd.20220342

中华皮肤科杂志 ›› 2025, e0220342.doi: 10.35541/cjd.20220342

• 综述 • 下一篇

Janus激酶抑制剂在中重度特应性皮炎中的应用进展

李明李妍李邻峰

首都医科大学附属北京友谊医院皮肤科，北京 100050

收稿日期:2022-05-13 修回日期:2023-08-04 发布日期:2025-01-23
通讯作者: 李邻峰 E-mail:zoonli@sina.com

JAK inhibitors for the treatment of moderate-to-severe atopic dermatitis

Li Ming, Li Yan, Li Linfeng

Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Received:2022-05-13 Revised:2023-08-04 Published:2025-01-23
Contact: Li Linfeng E-mail:zoonli@sina.com

摘要/Abstract

摘要： 【摘要】特应性皮炎是一种常见的慢性炎症性皮肤病，发病机制尚不清楚，多种炎症细胞及其细胞因子参与其中。Janus激酶（JAK）抑制剂可以抑制JAK-信号转导和转录激活因子（STAT）通路，阻断相关细胞因子的信号转导，减轻炎症反应。目前多种JAK抑制剂获批中重度特应性皮炎适应证，临床研究显示其良好的疗效和安全性。本文系统回顾不同种类JAK抑制剂治疗中重度特应性皮炎的机制、疗效和安全性。

关键词: 皮炎, 特应性, Janus激酶类, 信号传导通路, 疗效, 安全性

Abstract: 【Abstract】 Atopic dermatitis （AD） is a common chronic inflammatory skin disease with unclear pathogenesis. Multiple inflammatory cells and relevant cytokines are involved in its occurrence. Janus kinase（JAK） inhibitors can suppress the JAK-signal transducer and activator of transcription （STAT） signaling pathway, block the signal transduction of relevant cytokines, and reduce inflammatory responses. Currently, several JAK inhibitors have been approved for the treatment of moderate-to-severe AD, and clinical trials have demonstrated their good efficacy and safety. This review summarizes the mechanisms of action, efficacy and safety of different types of JAK inhibitors for the treatment of moderate-to-severe AD.

Key words: Dermatitis, atopic, Janus kinases, Signal transduction pathway, Efficacy, Safety

中图分类号:

李明李妍李邻峰. Janus激酶抑制剂在中重度特应性皮炎中的应用进展[J]. 中华皮肤科杂志, 2025,e0220342. doi:10.35541/cjd.20220342

Li Ming, Li Yan, Li Linfeng. JAK inhibitors for the treatment of moderate-to-severe atopic dermatitis[J]. Chinese Journal of Dermatology,2025,e0220342. doi:10.35541/cjd.20220342

参考文献 26

［1］	Traidl S, Freimooser S, Werfel T. Janus kinase inhibitors for the therapy of atopic dermatitis［J］. Allergol Select, 2021,5:293⁃304. doi: 10.5414/ALX02272E.
［2］	Langan SM, Irvine AD, Weidinger S. Atopic dermatitis［J］. Lancet, 2020,396（10247）:345⁃360. doi: 10.1016/S0140⁃6736（20）31286⁃1.
［3］	Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate⁃to⁃severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase Ⅲ trials［J］. Br J Dermatol, 2020,183（2）:242⁃255. doi: 10.1111/bjd.18898.
［4］	刘擘, 宋晓婷, 廖双璐, 等. 巴瑞替尼治疗中重度特应性皮炎的疗效和安全性观察［J］. 中华皮肤科杂志, 2022,55（4）:304⁃307. doi: 10.35541/cjd.20210474.
［5］	Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial［J］. JAMA Dermatol, 2020,156（12）:1333⁃1343. doi: 10.1001/jamadermatol.2020.3260.
［6］	Silverberg JI, Simpson EL, Wollenberg A, et al. Long⁃term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials［J］. JAMA Dermatol, 2021,157（6）:691⁃699. doi: 10.1001/jamadermatol. 2021.1273.
［7］	Reich K, Simpson E, Wollenberg A, et al. Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate⁃to⁃severe atopic dermatitis in a randomized substudy from the long⁃term extension study BREEZE⁃AD3［J］. Br J Dermatol. 2023,188（2）:208⁃217. doi: 10.1093/bjd/ljac057.
［8］	Guttman⁃Yassky E, Teixeira HD, Simpson EL, et al. Once⁃daily upadacitinib versus placebo in adolescents and adults with moderate⁃to⁃severe atopic dermatitis （Measure Up 1 and Measure Up 2）: results from two replicate double⁃blind, randomised controlled phase 3 trials［J］. Lancet, 2021,397（10290）:2151⁃2168. doi: 10.1016/S0140⁃6736（21）00588⁃2.
［9］	Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow⁃up data from the Measure Up 1 and Measure Up 2 randomized clinical trials［J］. JAMA Dermatol, 2022,158（4）:404⁃413. doi: 10.1001/jamadermatol.2022.0029.
［10］	Reich K, Teixeira HD, de Bruin⁃Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate⁃to⁃severe atopic dermatitis （AD Up）: results from a randomised, double⁃blind, placebo⁃controlled, phase 3 trial［J］. Lancet, 2021,397（10290）:2169⁃2181. doi: 10.1016/S0140⁃6736（21）00589⁃4.
［11］	Silverberg JI, de Bruin⁃Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD Up study results［J］. J Allergy Clin Immunol, 2022,149（3）:977⁃987.e14. doi: 10.1016/j.jaci.2021.07.036.
［12］	Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate⁃to⁃severe atopic dermatitis: a randomized clinical trial［J］. JAMA Dermatol, 2021,157（9）:1047⁃1055. doi: 10.1001/jamadermatol. 2021.3023.
［13］	Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate⁃to⁃severe atopic dermatitis: a randomized clinical trial［J］. JAMA Dermatol, 2020,156（8）:863⁃873. doi: 10.1001/jamadermatol.2020.1406.
［14］	Tong Z, Zhang Y, Zhou K, et al. An observational study of abrocitinib in adults with moderate⁃to⁃severe atopic dermatitis after switching from dupilumab［J］. J Am Acad Dermatol, 2023,89（4）:826⁃828. doi: 10.1016/j.jaad.2023. 05.077.
［15］	Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate⁃to⁃severe atopic dermatitis: The JADE TEEN randomized clinical trial［J］. JAMA Dermatol, 2021,157（10）:1165⁃1173. doi: 10.1001/jamadermatol.2021.2830.
［16］	Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis［J］. N Engl J Med, 2021,384（12）:1101⁃1112. doi: 10.1056/NEJMoa2019380.
［17］	Alexis A, de Bruin⁃Weller M, Weidinger S, et al. Rapidity of improvement in signs/symptoms of moderate⁃to⁃severe atopic dermatitis by body region with abrocitinib in the phase 3 JADE COMPARE study［J］. Dermatol Ther （Heidelb）, 2022,12（3）:771⁃785. doi: 10.1007/s13555⁃022⁃00694⁃1.
［18］	Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate⁃to⁃severe atopic dermatitis: results from the JAK1 atopic dermatitis efficacy and safety （JADE） REGIMEN phase 3 trial［J］. J Am Acad Dermatol, 2022,86（1）:104⁃112. doi: 10. 1016/j.jaad.2021.05.075.
［19］	Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials［J］. J Eur Acad Dermatol Venereol, 2021,35（2）:476⁃485. doi: 10.1111/jdv.16948.
［20］	Katoh N, Ohya Y, Murota H, et al. A phase 3 randomized, multicenter, double⁃blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate⁃to⁃severe atopic dermatitis in Japan （Rising Up）: an interim 24⁃week analysis［J］. JAAD Int, 2022,6:27⁃36. doi: 10.1016/j.jdin.2021.11.001.
［21］	Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate⁃to⁃severe atopic dermatitis from the phaseⅡ and phase Ⅲ clinical trial program［J］. Am J Clin Dermatol, 2021,22（5）:693⁃707. doi: 10.1007/s40257⁃021⁃00618⁃3.
［22］	Torres T, Gonçalo M, Paiva Lopes MJ, et al. Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients［J］. Drugs Context, 2021,10doi: 10.7573/dic.2021⁃9⁃5.
［23］	Mumford BP, Gibson A, Chong AH. Repigmentation of vitiligo with oral baricitinib［J］. Australas J Dermatol, 2020,61（4）:374⁃376. doi: 10.1111/ajd.13348.
［24］	Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase （JAK） 1/JAK2 inhibitor, in patients with moderate⁃to⁃severe psoriasis［J］. Br J Dermatol, 2016,174（6）:1266⁃1276. doi: 10.1111/bjd.14403.
［25］	Gambardella A, Licata G, Calabrese G, et al. Dual efficacy of upadacitinib in 2 patients with concomitant severe atopic dermatitis and alopecia areata［J］. Dermatitis, 2021,32（1S）:e85⁃e86. doi: 10.1097/DER.0000000000000780.
［26］	Bennett M, Moussa A, Sinclair R. Successful treatment of chronic severe alopecia areata with abrocitinib［J］. Australas J Dermatol, 2022,63（2）:274⁃276. doi: 10.1111/ajd.13836.

[1]	许焯红胡煜顾恒. 间充质干细胞来源的外泌体在皮肤病中的作用[J]. 中华皮肤科杂志, 2025, 0(3): 20220881-e20220881.
[2]	叶慧邓仕琳梁景耀张锡宝. 特应性皮炎复发控制与组织驻留记忆性T细胞的相关性研究进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240192-e20240192.
[3]	汪锋夏汝山. 毛囊黑素干细胞在白发中的研究进展[J]. 中华皮肤科杂志, 2025, 58(2): 182-185.
[4]	李安琪孙秋宁. 脑源性神经营养因子与皮肤病[J]. 中华皮肤科杂志, 2025, 58(2): 190-193.
[5]	刘雅妮赵倩刘源张俊艳王惠平. 特应性皮炎控制工具评估病情控制情况的有效性验证[J]. 中华皮肤科杂志, 2025, 58(2): 154-160.
[6]	李红毅吴盼盼吴汶丰彭俊胜刘秦陆颖珊董金典杨志波. 罗浮山百草油治疗白纹伊蚊叮咬的临床疗效与安全性配对自身平行对照研究[J]. 中华皮肤科杂志, 2025, 58(2): 178-181.
[7]	孟晓王俊慧颜志芳王宁崔炳南. 体视学测量在中药面膜治疗单纯色素型黄褐斑中的疗效评价研究[J]. 中华皮肤科杂志, 2025, 58(1): 53-59.
[8]	王博郑捷. 老年银屑病和特应性皮炎患者生物制剂及小分子药物治疗中应注意的问题[J]. 中华皮肤科杂志, 2025, 58(1): 72-75.
[9]	杨子靖陈利红阮叶平文莞廷张嘉艺王海伦潘萌赵肖庆. 度普利尤单抗治疗老年性特应性皮炎的疗效及安全性研究[J]. 中华皮肤科杂志, 2025, 58(1): 65-69.
[10]	王迪张瑞珺康玉英. 脂溢性皮炎的发病机制及治疗研究进展[J]. 中华皮肤科杂志, 2025, 58(1): 89-92.
[11]	邹先彪陈锦纯曾悦郝轶. [开放获取] 超声检查在皮肤科的应用前景[J]. 中华皮肤科杂志, 2024, 57(9): 785-790.
[12]	谢媛媛刘宇甄曾荣. 皮肤影像技术在寻常痤疮诊疗中的应用进展[J]. 中华皮肤科杂志, 2024, 57(8): 757-760.
[13]	罗莉张博娜吴畏汤文静李岳华刘晓莉马雅楠李翠翠齐梦岩孙妮石琼. [开放获取] 308 nm准分子激光与308 nm准分子光治疗194例儿童白癜风的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2024, 57(8): 721-727.
[14]	林子沅庞天怡武静文靳慧. 多环芳烃在炎症性皮肤病发生发展中的作用研究进展[J]. 中华皮肤科杂志, 2024, 57(8): 765-769.
[15]	胡清洁徐康朱虹姚煦. 老年特应性皮炎患者使用度普利尤单抗治疗的药物留存率及安全性回顾性队列分析[J]. 中华皮肤科杂志, 2024, 57(7): 632-636.

Janus激酶抑制剂在中重度特应性皮炎中的应用进展

JAK inhibitors for the treatment of moderate-to-severe atopic dermatitis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 26

相关文章 15

Metrics

本文评价

推荐阅读 10